{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:25:40Z","timestamp":1777890340615,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"\n Background<\/jats:title>\n Atopic Dermatitis (AD) in children is a common chronic skin condition characterized by dry, itchy and inflamed skin. Various treatments have been applied in the management of AD in children, but the differences in efficacy of different treatment options have not been systematically summarized. The aim of this study was to compare the efficacy of different treatments for atopic dermatitis in children by network meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a systematic literature search to select randomized controlled trials (RCTs) that met the inclusion criteria. Databases included PubMed, EMBASE, Cochrane Library, and Web of Science, with a March 10, 2025, search deadline. Certainty of evidence was graded using the CINeMA tool, and risk of bias was assessed using risk of bias 2.0. The efficacy of different treatment regimens was compared using Bayesian network meta-analysis with R software. The primary outcome indicators were the SCORAD (Clinical Score for Atopic Dermatitis) and EASI (Atopic Dermatitis Area and Severity Index) scores.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirty-two randomized controlled trials (n=3961) were included. Meta-analysis showed Dupilumab was more effective than Melatonin, Probiotics, SCG, Synbiotic, and Vitamin D for SCORAD. Cumulative probability rankings indicated Dupilumab (96.0%), Tralokinumab (86.8%), and PEC (69.2%) as the top treatments. For EASI, Pimecrolimus, Dupilumab, and Nemolizumab were superior to Probiotics, with Pimecrolimus showing the highest efficacy (99.9%).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Dupilumab may offer greater benefits in reducing SCORAD scores, while Pimecrolimus appears to be more effective for improving EASI. These treatments show potential as favorable options for managing pediatric atopic dermatitis.<\/jats:p>\n <\/jats:sec>\n \n Systematic Review Registration<\/jats:title>\n \n https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420250650919<\/jats:ext-link>\n , identifier CRD420250650919.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1676852","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:47Z","timestamp":1777613747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement"],"prefix":"10.3389","volume":"17","author":[{"given":"Liu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.013","article-title":"Risk of atopic dermatitis and the atopic march paradigm in children of mothers with atopic illnesses: a birth cohort study from the United Kingdom","volume":"90","author":"Chiesa Fuxench","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01742-1","article-title":"Biological therapy for young children with atopic dermatitis","volume":"400","author":"Halling","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad325","article-title":"Atopic dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the UK","volume":"190","author":"Fuxench","year":"2023","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac105","article-title":"Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis","volume":"188","author":"Hu","year":"2023","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.16265","article-title":"Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: a population-based cohort study","volume":"79","author":"Tsai","year":"2024","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20260","article-title":"The complex relationship between maternal smoking and atopic dermatitis in children","volume":"38","author":"Vestergaard","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18564","article-title":"Atopic dermatitis and risk of major neuropsychiatric disorders in children: a population-based cohort study","volume":"37","author":"Wan","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.jaip.2021.12.012","article-title":"Burden and characteristics of skin pain among children with atopic dermatitis","volume":"10","author":"Cheng","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-78814-0_23","article-title":"Atopic dermatitis in children and adults\u2014diagnosis and treatment","volume":"120","author":"Wollenberg","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2023.12.005","article-title":"Unraveling the link between atopic dermatitis and autoimmune diseases in children: insights from a large-scale cohort study with 15-year follow-up and shared gene ontology analysis","volume":"73","author":"Ahn","year":"2024","journal-title":"Allergol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2023.127595","article-title":"Atopic dermatitis: pathophysiology, microbiota, and metabolome - a comprehensive review","volume":"281","author":"Mohammad","year":"2024","journal-title":"Microbiol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15344","article-title":"Severe atopic dermatitis in early infancy: characteristics, challenges and new perspectives in clinical practice","volume":"22","author":"Weins","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.08.717","article-title":"Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review","volume":"159","author":"Maleki-Yazdi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.046","article-title":"Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis","volume":"92","author":"Paller","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1111\/all.16147","article-title":"Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: results of the German TREATkids registry","volume":"79","author":"St\u00f6lzl","year":"2024","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac116","article-title":"How we treat atopic dermatitis now and how that will change over the next 5 years","volume":"188","author":"Flohr","year":"2023","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaci.2024.04.009","article-title":"Biologic and small-molecule therapy for treating moderate to severe atopic dermatitis: mechanistic considerations","volume":"154","author":"Rothenberg-Lausell","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19807","article-title":"Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis","volume":"38","author":"Ryan Wolf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2020.102433","article-title":"The reporting quality and risk of bias of randomized controlled trials of acupuncture for migraine: methodological study based on STRICTA and RoB 2.0","volume":"52","author":"Lu","year":"2020","journal-title":"Compl Ther Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campb Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2024.08.031","article-title":"Prostate cancer therapy cardiotoxicity map (PROXMAP) for advanced disease states: a systematic review and network meta-analysis with Bayesian modeling of treatment histories","volume":"87","author":"Aziz","year":"2025","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ctim.2017.10.003","article-title":"A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): a randomized, placebo-controlled clinical trial","volume":"35","author":"Abbasi","year":"2017","journal-title":"Compl Ther Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e128","article-title":"Effects of Lactobacillus pentosus in children with allergen-sensitized atopic dermatitis","volume":"35","author":"Ahn","year":"2020","journal-title":"J Kor Med Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12978","article-title":"The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial","volume":"29","author":"Ardakani","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.946380","article-title":"A randomised, controlled trial of a 4% cutaneous emulsion of sodium cromoglicate in treatment of atopic dermatitis in children","volume":"26","author":"Berth-Jones","year":"2015","journal-title":"J Dermatol Treat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19959","article-title":"Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: a randomized controlled trial","volume":"38","author":"Borzutzky","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00128071-200203030-00004","article-title":"Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial","volume":"170","author":"Chang","year":"2016","journal-title":"JAMA Pediatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034077","article-title":"Long-term use of a 4% sodium cromoglicate cutaneous emulsion in the treatment of moderate to severe atopic dermatitis in children","volume":"26","author":"Edwards","year":"2015","journal-title":"J Dermatol Treat"},{"key":"B32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"B33","article-title":"Effect of a new synbiotic mixture on atopic dermatitis in children: a randomized-controlled trial","volume":"21","author":"Farid","year":"2011","journal-title":"Iran J Pediatr"},{"key":"B34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ced\/llad007","article-title":"Randomized double-blind placebo-controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and use of corticosteroids in children and adolescents with atopic dermatitis","volume":"48","author":"Fe\u00edto-Rodr\u00edguez","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07558.x","article-title":"Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis","volume":"155","author":"F\u00f6lster-Holst","year":"2006","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2165\/11531420-000000000-00000","article-title":"Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial","volume":"11","author":"Gerasimov","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1111\/j.1398-9995.2007.01543.x","article-title":"Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy","volume":"62","author":"Gr\u00fcber","year":"2007","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2018.07.003","article-title":"A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis","volume":"23","author":"Han","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13269","article-title":"A randomized trial of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) for treating atopic dermatitis","volume":"31","author":"Jeong","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418805744","article-title":"Vitamin D level and supplementation in pediatric atopic dermatitis: a randomized controlled trial","volume":"23","author":"Lara-Corrales","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/1871530320666201023125411","article-title":"Efficacy of short term topical Malva sylvestris L. cream in pediatric patients with atopic dermatitis: a randomized double-blind placebo-controlled clinical trial","volume":"21","author":"Meysami","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5863\/1551-6776-28.1.29","article-title":"Evaluating the effect of eicosapentaenoic acid in children with atopic dermatitis: a randomized triple-blind clinical trial","volume":"28","author":"Mirrahimi","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamadermatol.2017.3647","article-title":"Effect of oral administration of a mixture of probiotic strains on SCORAD index and use of topical steroids in young patients with moderate atopic dermatitis: a randomized clinical trial","volume":"154","author":"Navarro-L\u00f3pez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202407.1619.v1","article-title":"Effect of omega-3 polyunsaturated fatty acid supplementation on clinical outcome of atopic dermatitis in children","volume":"16","author":"Niseteo","year":"2024","journal-title":"Nutrients"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.reval.2023.103411","article-title":"Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis","volume":"41","author":"Paller","year":"2024","journal-title":"Adv Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/1346-8138.15137","article-title":"Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2\u201314 years with atopic dermatitis","volume":"47","author":"Saeki","year":"2020","journal-title":"J Dermatol"},{"key":"B47","article-title":"Synbiotics could not reduce the scoring of childhood atopic dermatitis (SCORAD): a randomized double blind placebo-controlled trial","volume":"10","author":"Shafiei","year":"2011","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/bjd\/ljad096","article-title":"Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)","volume":"189","author":"Torrelo","year":"2023","journal-title":"Br J Dermatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2015.10.003","article-title":"Evaluation of efficacy and safety of Lactobacillus rhamnosus in children aged 4\u201348 months with atopic dermatitis: an 8-week, double-blind, randomized, placebo-controlled study","volume":"50","author":"Wu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2014.6.3.208","article-title":"Efficacy of probiotic therapy on atopic dermatitis in children: a randomized, double-blind, placebo-controlled trial","volume":"6","author":"Yang","year":"2014","journal-title":"Allergy Asthma Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2024","journal-title":"Br J Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2222.2010.03465.x","article-title":"Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial","volume":"40","author":"Van Der Aa","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.033","article-title":"Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.039","article-title":"Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study","volume":"91","author":"Hasan","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18434","article-title":"Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)","volume":"182","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.047","article-title":"Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial","volume":"88","author":"Beck","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00886-9","article-title":"Pimecrolimus for the treatment of atopic dermatitis in infants: an Asian perspective","volume":"13","author":"Chu","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1925077","article-title":"The prevention effect of probiotics against eczema in children: an update systematic review and meta-analysis","volume":"33","author":"Sun","year":"2022","journal-title":"J Dermatol Treat"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae344","article-title":"An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024","volume":"191","author":"Ardern-Jones","year":"2024","journal-title":"Br J Dermatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2023.4556","article-title":"Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children and sensitive skin areas","volume":"33","author":"Luger","year":"2023","journal-title":"Eur J Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15751","article-title":"Safety of topical medications in the management of paediatric atopic dermatitis: an updated systematic review","volume":"89","author":"Zhao","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1676852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:35:48Z","timestamp":1777613748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1676852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2026.1676852"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1676852","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1676852"}}